Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Blazesbon Mar 17, 2020 7:48pm
112 Views
Post# 30819397

RE:RE:A Question For The Old Hands

RE:RE:A Question For The Old HandsThank you Mugmods.  You have more than answered my questions.

I am aware of the Knight connection.  Goodman seems to be regarded as a knowledgeable operator who seeks deep value where acquisitions are concerned.

Thank you for the background of management with the Knight connection.  It reminds me somewhat of the role Eric Sprott plays with junior miners, seeding them with capital to fund exploration.  Sprott takes somewhat of a scattershot approach--he spent $150 million total buying pieces of 16 jr. miners last year.  

I recall after the 2B results were released the company hired someone to manage future partnerships.  That person may still be in place or augmented/supplanted by a new person--i seem to recall a hire in the last year with partnerships in the job description--BUT the goal of partnerships seems to be of primary importance.

When results of this phase of drug testing are released has management created reasonable expectations for the benefits of partnerships?

I believe future testing, phase three, depends upon the financial backing of partners.  Is that true?  If it's true do shareholders prefer the endorsement such a partnership implies or is there room for a contrary opinion that shareholders would be better served by the company going it alone funding testing bia share issues?

Thank you again.

.


Bullboard Posts